FIELD: biotechnology.
SUBSTANCE: invention relates to methods for preventing, inhibiting or treating one or more symptoms associated with a central nervous system disease, by intranasal, intrathecal, intracerebrovascular or intravenous introduction of rAAV encoding a gene product associated with a disease, e.g. a mammal, in which a gene product is absent or present at a lower level compared to a mammal not having the disease, in an amount effective, e.g. to provide cross-correction.
EFFECT: disclosed is an adeno-associated virus vector for therapeutic delivery into the central nervous system.
21 cl, 42 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VECTOR BASED ON ADENO-ASSOCIATED VIRUS FOR THERAPEUTIC DELIVERY TO CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2804953C2 |
| ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO CENTRAL NERVOUS SYSTEM | 2014 |
|
RU2692251C2 |
| ADENO-ASSOCIATED VIRUS-MEDIATED GENE TRANSFER INTO THE CENTRAL NERVOUS SYSTEM | 2014 |
|
RU2801511C1 |
| COMPOSITIONS AND METHODS OF TREATING MPS1 | 2014 |
|
RU2708318C2 |
| COMPOSITIONS, METHODS AND APPLICATIONS OF GENE TRANSFER FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2017 |
|
RU2805606C2 |
| METHODS AND COMPOSITIONS FOR BRAIN DISEASES TREATMENT | 2014 |
|
RU2664471C2 |
| ADENO-ASSOCIATED VIRUS VECTOR | 2015 |
|
RU2743382C2 |
| INTRATHECAL ADMINISTRATION OF VECTORS BASED ON ADENO ASSOCIATED VIRUSES FOR GENE THERAPY | 2016 |
|
RU2775138C2 |
| AAV-BASED HUNTINGTON'S DISEASE TREATMENT | 2017 |
|
RU2749971C2 |
| VECTORS AND SEQUENCES FOR TREATING DISEASES | 2011 |
|
RU2588667C2 |
